A Single-Arm Phase 2 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens

Trial Profile

A Single-Arm Phase 2 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Squamous Cell Non-Small Cell Lung Cancer Who Have Received At Least Two Prior Systemic Regimens

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Aug 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Non-small cell lung cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms CheckMate 063
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 02 Aug 2017 Planned End Date changed from 1 Aug 2016 to 30 Dec 2018.
    • 05 Apr 2017 Results of a biomarker analysis assessing soluble HLA-G and -E (sHLA-G/E) as potential biomarkers of clinical outcomes in patients with advanced, refractory squamous non-small cell lung cancer treated with nivolumab in CheckMate 063 study, presented at the 108th Annual Meeting of the American Association for Cancer Research.
    • 01 Oct 2016 Results of pooled analysis of three studies including this study published in the Journal of Thoracic Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top